Equity Profile

IBRX

ImmunityBio, Inc.

Health CareBiotechnology$7.2B

May7Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:30 AM EDT

ImmunityBio, Inc. Misses on EPS, Stock Down 7.4%

Metric	Actual	Expected	Surprise
EPS	$-0.62	N/A	-675.00%
Revenue	—	N/A	—

management commentary, guidance changes, and full analysis available with Pro.

ImmunityBio, Inc. Misses on EPS, Stock Down 7.4%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.62	N/A	-675.00%
Revenue	—	N/A	—

Management Commentary

Tone: Unknown

No transcript is on record for the earnings call, and the analysis is based solely on numerical results.

What It Means

ImmunityBio, Inc. reported a significant loss per share of $0.62, which contributed to a 7.4% decline in stock price following the announcement. The lack of revenue figures and guidance may raise concerns among investors about the company's financial health and future prospects. Overall, the results indicate challenges for the company in the current fiscal quarter.

Company Snapshot

ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapy treatments for cancer and infectious diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and is essential for assessing future potential.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapy treatments for cancer and infectious diseases. Operating in the health care sector, it aims to harness the body's immune system to fight diseases, which is a significant theme in modern medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-72.64%

Avg Stock Reaction

-0.28%

Last Quarter Recap

In the last quarter, ImmunityBio reported an EPS of -$0.06, beating expectations by 25%. The stock reacted positively, increasing by nearly 13% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for ImmunityBio are mixed as the company has shown a history of beating EPS estimates. However, the lack of revenue guidance adds uncertainty.

Bull Case

The optimistic view is that ImmunityBio will continue its trend of beating EPS estimates, potentially leading to a significant stock price increase.

Bear Case

On the other hand, if the company fails to provide clear revenue growth or guidance, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q1-2026?

The EPS figure will be closely watched as it can indicate the company's profitability and influence investor sentiment.

Will there be any guidance on revenue growth?

Clear revenue guidance is crucial for assessing the company's future prospects and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for ImmunityBio to exceed EPS expectations based on its recent performance trends.

Supporting Evidence

The company has beaten EPS estimates in 63% of the last 8 quarters.

Options are pricing a 14.16% move, suggesting significant volatility that may not align with historical performance.

Key Risk

If the EPS comes in above -$0.06, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around the company's ability to maintain its trend of beating EPS estimates while providing clear revenue guidance.

Bull Confirmed If

A positive EPS surprise of more than 25% would confirm the bull case.

Bear Confirmed If

An EPS miss below -$0.10 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.16%

Historical Avg

±7.9%

In line with history

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±7.7% while IBRX has averaged ±7.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

1.3%

30d HV

92.4%

Calls (1.2M)P/C Ratio: 0.20Puts (156K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ImmunityBio beats EPS expectations, history suggests the stock could rise by around 1.68% on average.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience a muted reaction.

Miss

If the company misses EPS estimates, history suggests a potential drop of about 4.38%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on ongoing clinical trials and their expected timelines.
2Details on cost management and operational efficiencies.
3Insights into market demand for their therapies.
4Any strategic partnerships or collaborations announced.
5Management's outlook on the competitive landscape.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

The Marzetti Company

Company Snapshot

ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapy treatments for cancer and infectious diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its market presence and is essential for assessing future potential.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-72.64%

Avg Stock Reaction

-0.28%

Last Quarter Recap

In the last quarter, ImmunityBio reported an EPS of -$0.06, beating expectations by 25%. The stock reacted positively, increasing by nearly 13% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for ImmunityBio are mixed as the company has shown a history of beating EPS estimates. However, the lack of revenue guidance adds uncertainty.

Bull Case

The optimistic view is that ImmunityBio will continue its trend of beating EPS estimates, potentially leading to a significant stock price increase.

Bear Case

On the other hand, if the company fails to provide clear revenue growth or guidance, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q1-2026?

The EPS figure will be closely watched as it can indicate the company's profitability and influence investor sentiment.

Will there be any guidance on revenue growth?

Clear revenue guidance is crucial for assessing the company's future prospects and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for ImmunityBio to exceed EPS expectations based on its recent performance trends.

Supporting Evidence

The company has beaten EPS estimates in 63% of the last 8 quarters.

Options are pricing a 14.16% move, suggesting significant volatility that may not align with historical performance.

Key Risk

If the EPS comes in above -$0.06, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around the company's ability to maintain its trend of beating EPS estimates while providing clear revenue guidance.

Bull Confirmed If

A positive EPS surprise of more than 25% would confirm the bull case.

Bear Confirmed If

An EPS miss below -$0.10 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.16%

Historical Avg

±7.9%

In line with history

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±7.7% while IBRX has averaged ±7.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

1.3%

30d HV

92.4%

Calls (1.2M)P/C Ratio: 0.20Puts (156K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ImmunityBio beats EPS expectations, history suggests the stock could rise by around 1.68% on average.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience a muted reaction.

Miss

If the company misses EPS estimates, history suggests a potential drop of about 4.38%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on ongoing clinical trials and their expected timelines.
2Details on cost management and operational efficiencies.
3Insights into market demand for their therapies.
4Any strategic partnerships or collaborations announced.
5Management's outlook on the competitive landscape.